

# Dexian Zheng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9079871/publications.pdf>

Version: 2024-02-01

80  
papers

10,134  
citations

159585

30  
h-index

69250

77  
g-index

80  
all docs

80  
docs citations

80  
times ranked

23735  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. <i>Nature Medicine</i> , 2005, 11, 875-879.	30.7	2,986
3	The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. <i>FASEB Journal</i> , 2017, 31, 893-903.	0.5	158
4	Microwave-assisted Protein Preparation and Enzymatic Digestion in Proteomics. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 769-776.	3.8	138
5	Human urine proteome analysis by three separation approaches. <i>Proteomics</i> , 2005, 5, 4994-5001.	2.2	134
6	Overexpression of Soluble TRAIL Induces Apoptosis in Human Lung Adenocarcinoma and Inhibits Growth of Tumor Xenografts in Nude Mice. <i>Cancer Research</i> , 2005, 65, 1687-1692.	0.9	116
7	The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat. <i>Biomaterials</i> , 2009, 30, 4014-4020.	11.4	113
8	Concanavalin A-captured Glycoproteins in Healthy Human Urine. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 560-562.	3.8	109
9	A double feedback loop mediated by microRNA-23a/27a/24-2 regulates M1 versus M2 macrophage polarization and thus regulates cancer progression. <i>Oncotarget</i> , 2016, 7, 13502-13519.	1.8	103
10	Dysregulated expression of miR-146a contributes to age-related dysfunction of macrophages. <i>Aging Cell</i> , 2012, 11, 29-40.	6.7	95
11	Functions of miR-146a and miR-222 in Tumor-associated Macrophages in Breast Cancer. <i>Scientific Reports</i> , 2015, 5, 18648.	3.3	75
12	A Novel Anti-human DR5 Monoclonal Antibody with Tumoricidal Activity Induces Caspase-dependent and Caspase-independent Cell Death. <i>Journal of Biological Chemistry</i> , 2005, 280, 41940-41952.	3.4	71
13	Over-expression of CD3 $\mu$ transgenes blocks T lymphocyte development. <i>International Immunology</i> , 1995, 7, 435-448.	4.0	51
14	TRAIL receptor mediates inflammatory cytokine release in an NF- $\kappa$ B-dependent manner. <i>Cell Research</i> , 2009, 19, 758-767.	12.0	46
15	HIV Infection Enhances TRAIL-Induced Cell Death in Macrophage by Down-Regulating Decoy Receptor Expression and Generation of Reactive Oxygen Species. <i>PLoS ONE</i> , 2011, 6, e18291.	2.5	46
16	Tyrosine Phosphorylation of the CD3 $\mu$ Subunit of the T Cell Antigen Receptor Mediates Enhanced Association with Phosphatidylinositol 3-Kinase in Jurkat T Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 25310-25318.	3.4	45
17	Tumor necrosis factor-related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype. <i>Molecular Biology of the Cell</i> , 2015, 26, 3178-3189.	2.1	44
18	AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. <i>Life Sciences</i> , 2008, 82, 1154-1161.	4.3	41

#	ARTICLE	IF	CITATIONS
19	Expression of human soluble TRAIL in Chlamydomonas reinhardtii chloroplast. Science Bulletin, 2006, 51, 1703-1709.	1.7	40
20	Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappaB. FEBS Journal, 2009, 276, 581-593.	4.7	40
21	Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology, 2005, 42, 1355-1363.	7.3	39
22	Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer, 2011, 11, 54.	2.6	39
23	TRAIL-induced miR-146a expression suppresses CXCR4-mediated human breast cancer migration. FEBS Journal, 2013, 280, 3340-3353.	4.7	39
24	Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. International Journal of Cancer, 2005, 116, 314-321.	5.1	38
25	GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90. Oncogene, 2018, 37, 4505-4517.	5.9	36
26	Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells. Neuroscience Research, 2007, 59, 40-46.	1.9	35
27	AMASS: Software for Automatically Validating the Quality of MS/MS Spectrum from SEQUEST Results. Molecular and Cellular Proteomics, 2004, 3, 1194-1199.	3.8	33
28	Dynamic urinary proteomic analysis reveals stable proteins to be potential biomarkers. Proteomics - Clinical Applications, 2009, 3, 370-382.	1.6	32
29	PKC $\zeta$ protects human breast tumor MCF-7 cells against tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis. Journal of Cellular Biochemistry, 2005, 96, 522-532.	2.6	31
30	Transcriptome Identified lncRNAs Associated with Renal Fibrosis in UUO Rat Model. Frontiers in Physiology, 2017, 8, 658.	2.8	31
31	Human T-Cell Leukemia Virus Type 1 Tax-Deregulated Autophagy Pathway and c-FLIP Expression Contribute to Resistance against Death Receptor-Mediated Apoptosis. Journal of Virology, 2014, 88, 2786-2798.	3.4	30
32	Combination of AAV-TRAIL with miR-221-Zip Therapeutic Strategy Overcomes the Resistance to TRAIL Induced Apoptosis in Liver Cancer. Theranostics, 2017, 7, 3228-3242.	10.0	30
33	An update on gene therapy in China. Current Opinion in Molecular Therapeutics, 2009, 11, 547-53.	2.8	29
34	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces chemotactic migration of monocytes via a death receptor 4-mediated RhoGTPase pathway. Molecular Immunology, 2010, 47, 2475-2484.	2.2	25
35	TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis. Cancer Immunology, Immunotherapy, 2013, 62, 653-663.	4.2	25
36	TRAIL: A Potential Agent for Cancer Therapy. Current Molecular Medicine, 2003, 3, 727-736.	1.3	24

#	ARTICLE	IF	CITATIONS
37	Therapeutic Expression of an Anti-Death Receptor 5 Single-Chain Fixed-Variable Region Prevents Tumor Growth in Mice. <i>Cancer Research</i> , 2006, 66, 11946-11953.	0.9	23
38	A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors. <i>Theranostics</i> , 2019, 9, 5412-5423.	10.0	23
39	Tax1 enhances cancer cell proliferation via Rasâ€“Rafâ€“MEKâ€“ERK signaling pathway. <i>IUBMB Life</i> , 2009, 61, 685-692.	3.4	22
40	<scp>TRAIL</scp> receptor deficiency sensitizes mice to dextran sodium sulphateâ€“induced colitis and colitisâ€“associated carcinogenesis. <i>Immunology</i> , 2014, 141, 211-221.	4.4	22
41	RIP1 modulates death receptor mediated apoptosis and autophagy in macrophages. <i>Molecular Oncology</i> , 2015, 9, 806-817.	4.6	22
42	An agonistic monoclonal antibody against DR5 induces ROS production, sustained JNK activation and Endo G release in Jurkat leukemia cells. <i>Cell Research</i> , 2009, 19, 984-995.	12.0	20
43	Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1007-1018.	4.1	20
44	2A Peptide-based, Lentivirus-mediated Anti-death Receptor 5 Chimeric Antibody Expression Prevents Tumor Growth in Nude Mice. <i>Molecular Therapy</i> , 2012, 20, 46-53.	8.2	20
45	Mmu-miR-125b overexpression suppresses NO production in activated macrophages by targeting eEF2K and CCNA2. <i>BMC Cancer</i> , 2016, 16, 252.	2.6	19
46	Comparative Proteome Analysis of Breast Cancer and Normal Breast. <i>Molecular Biotechnology</i> , 2005, 29, 233-244.	2.4	18
47	An Integrated Machine Learning System to Computationally Screen Protein Databases for Protein Binding Peptide Ligands. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1224-1232.	3.8	17
48	Alpha 1â€“antichymotrypsin/SerpinA3 is a novel target of orphan nuclear receptor Nur77. <i>FEBS Journal</i> , 2008, 275, 1025-1038.	4.7	17
49	Dysregulated expression of miR-101b and miR-26b lead to age-associated increase in LPS-induced COX-2 expression in murine macrophage. <i>Age</i> , 2015, 37, 97.	3.0	16
50	Molecular Therapeutics of HBV. <i>Current Gene Therapy</i> , 2003, 3, 341-355.	2.0	16
51	Death receptor 5â€“recruited raft components contributes to the sensitivity of Jurkat leukemia cell lines to TRAILâ€“induced cell death. <i>IUBMB Life</i> , 2009, 61, 261-267.	3.4	15
52	Sp1 is involved in 8-chloro-adenosine-upregulated death receptor 5 expression in human hepatoma cells. <i>Oncology Reports</i> , 2008, 19, 177-85.	2.6	15
53	Erbin-regulated Sensitivity of MCF-7 Breast Cancer Cells to TRAIL via ErbB2/AKT/NF-ÂˆB Pathway. <i>Journal of Biochemistry</i> , 2007, 143, 793-801.	1.7	14
54	Formyl peptide receptor-like 1 mediated endogenous TRAIL gene expression with tumoricidal activity. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2618-2625.	4.1	13

#	ARTICLE	IF	CITATIONS
55	Internalization and half-life of membrane-bound macrophage colony-stimulating factor. <i>Science Bulletin</i> , 2000, 45, 1697-1703.	1.7	12
56	Epirubicin potentiates recombinant adeno-associated virus type 2/5-mediated TRAIL expression in fibroblast-like synoviocytes and augments the antiarthritic effects of rAAV2/5-TRAIL. <i>Arthritis and Rheumatism</i> , 2012, 64, 1345-1354.	6.7	12
57	Adeno-associated virus-mediated anti-DR5 chimeric antibody expression suppresses human tumor growth in nude mice. <i>Cancer Letters</i> , 2011, 302, 119-127.	7.2	11
58	A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-2 monoclonal antibody induces apoptotic and autophagic cell death. <i>IUBMB Life</i> , 2017, 69, 735-744.	3.4	10
59	Antibody gene therapy: an attractive approach for the treatment of cancers and other chronic diseases. <i>Cell Research</i> , 2007, 17, 303-306.	12.0	9
60	Knockdown of FLIP enhanced AD5-10 anti-death receptor 5 monoclonal antibody-induced apoptosis in human lung cancer cells. <i>Cancer Science</i> , 2009, 100, 940-947.	3.9	9
61	A Systematical Analysis of Tryptic Peptide Identification with Reverse Phase Liquid Chromatography and Electrospray Ion Trap Mass Spectrometry. <i>Genomics, Proteomics and Bioinformatics</i> , 2004, 2, 174-183.	6.9	8
62	A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth. <i>IUBMB Life</i> , 2012, 64, 757-765.	3.4	8
63	Comparative Proteome Analysis of Splenic Lymphocytes in Senescence-Accelerated Mice. <i>Gerontology</i> , 2009, 55, 559-569.	2.8	6
64	Nucleic Acids in Protein Samples Interfere with Phosphopeptide Identification by Immobilized-Metal-Ion Affinity Chromatography and Mass Spectrometry. <i>Molecular Biotechnology</i> , 2009, 43, 59-66.	2.4	6
65	Targeting a Novel N-terminal Epitope of Death Receptor 5 Triggers Tumor Cell Death*. <i>Journal of Biological Chemistry</i> , 2010, 285, 8953-8966.	3.4	6
66	Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 329-339.	4.4	6
67	8-Chloro-adenosine sensitizes a human hepatoma cell line to TRAIL-induced apoptosis by caspase-dependent and -independent pathways. <i>Oncology Reports</i> , 2004, 12, 193-9.	2.6	6
68	v-Fos transformation effector binds with CD2 cytoplasmic tail. <i>Science Bulletin</i> , 2006, 51, 38-47.	1.7	5
69	Analysis of the ligand-binding domain of macrophage colony-stimulating receptor. <i>Science Bulletin</i> , 2000, 45, 1191-1195.	1.7	4
70	Recombinant sTRAIL induces cell death of tumor cell lines as well as primary cancer cells. <i>Science Bulletin</i> , 1999, 44, 1306-1309.	1.7	3
71	PRMT5 suppresses DR4-mediated CCL20 release via NF- $\kappa$ B pathway. <i>Science Bulletin</i> , 2012, 57, 4351-4355.	1.7	3
72	T lymphocyte apoptosis induced by CD8 $\mu$ chimera. <i>Science Bulletin</i> , 1997, 42, 222-227.	1.7	2

#	ARTICLE	IF	CITATIONS
73	Z-ajoene induces tumor cells to die by apoptosis. Science Bulletin, 1998, 43, 1135-1140.	1.7	2
74	Modulating multidrug resistance through inhibiting of protein kinase C activity by phenothiazines. Science Bulletin, 1998, 43, 1196-1200.	1.7	2
75	PI3K/Akt signaling pathway involved in regulation of T lymphocyte activation and apoptosis mediated by CD3 $\mu$ . Science Bulletin, 2001, 46, 568-570.	1.7	2
76	Two tyrosines in CD3s-ITAM are required to induce T lymphocyte apoptosis. Science Bulletin, 1998, 43, 1480-1485.	1.7	1
77	Cloning and identification of a novel binding protein of CD2 cytoplasmic domain. Science Bulletin, 2000, 45, 2263-2267.	1.7	1
78	Mitogenic Effect of Polyclonal Anti-Porcine Lymphocyte E-Receptor Antiserum IgG. Immunological Investigations, 1987, 16, 363-370.	2.0	0
79	8-chloroadenosine induces apoptosis in human MOLT-4 cell line. Science Bulletin, 1997, 42, 592-597.	1.7	0
80	A highlight of recent advances in immunology. Science China Life Sciences, 2011, 54, 1151-1152.	4.9	0